249 related articles for article (PubMed ID: 36849969)
21. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
22. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
[TBL] [Abstract][Full Text] [Related]
24. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
Schneider LS; Dagerman KS; Higgins JP; McShane R
Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
[TBL] [Abstract][Full Text] [Related]
25. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
27. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
28. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
29. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
30. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Xiao S; Chan P; Wang T; Hong Z; Wang S; Kuang W; He J; Pan X; Zhou Y; Ji Y; Wang L; Cheng Y; Peng Y; Ye Q; Wang X; Wu Y; Qu Q; Chen S; Li S; Chen W; Xu J; Peng D; Zhao Z; Li Y; Zhang J; Du Y; Chen W; Fan D; Yan Y; Liu X; Zhang W; Luo B; Wu W; Shen L; Liu C; Mao P; Wang Q; Zhao Q; Guo Q; Zhou Y; Li Y; Jiang L; Ren W; Ouyang Y; Wang Y; Liu S; Jia J; Zhang N; Liu Z; He R; Feng T; Lu W; Tang H; Gao P; Zhang Y; Chen L; Wang L; Yin Y; Xu Q; Xiao J; Cong L; Cheng X; Zhang H; Gao D; Xia M; Lian T; Peng G; Zhang X; Jiao B; Hu H; Chen X; Guan Y; Cui R; Huang Q; Xin X; Chen H; Ding Y; Zhang J; Feng T; Cantillon M; Chen K; Cummings JL; Ding J; Geng M; Zhang Z
Alzheimers Res Ther; 2021 Mar; 13(1):62. PubMed ID: 33731209
[TBL] [Abstract][Full Text] [Related]
31. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
32. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
33. Rivastigmine for Alzheimer's disease.
Birks JS; Chong LY; Grimley Evans J
Cochrane Database Syst Rev; 2015 Sep; 9(9):CD001191. PubMed ID: 26393402
[TBL] [Abstract][Full Text] [Related]
34. Galantamine for Alzheimer's disease.
Loy C; Schneider L
Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
[TBL] [Abstract][Full Text] [Related]
35. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
Koh SH; Kwon HS; Choi SH; Jeong JH; Na HR; Lee CN; Yang Y; Lee AY; Lee JH; Park KW; Han HJ; Kim BC; Park JS; Lee JY; Kim S; Lee KY
Alzheimers Res Ther; 2021 Mar; 13(1):66. PubMed ID: 33771205
[TBL] [Abstract][Full Text] [Related]
37. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
[TBL] [Abstract][Full Text] [Related]
38. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
39. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]